How did Lantheus Holdings' revenue and expenses shift in Q4 2024 compared to previous quarters?

**Lantheus Holdings experienced significant revenue growth in Q4 2024 compared to the previous quarter.** Here's a detailed analysis:

1. **Revenue Shift**:
- Lantheus reported worldwide revenue of $378.7 million in Q3 2024.
- In Q4 2024, revenue increased to $391.1 million, indicating a growth of approximately 3.8%.
- The full-year revenue for 2024 reached $1.53 billion, reflecting an 18.3% growth from the previous year.
2. **Expense Shift**:
- There are no available data on the expenses in Q4 2024 compared to the previous quarter.
- However, the company reported an increase in operating expenses in Q3 2024, which were driven by business development activities and potential acquisitions.
3. **Financial Performance**:
- Lantheus reported a net income of $131.1 million in Q4 2024, which was slightly down from $132.0 million in the same period of the previous year.
- Adjusted net income saw a 20.4% increase, reaching $124.1 million compared to $103.1 million in the previous year.
4. **Sales Performance of Key Products**:
- PYLARIFY, the flagship diagnostic agent, generated sales of $259.8 million in Q3 2024.
- In Q4 2024, PYLARIFY sales increased to $266 million, marking a 15.7% rise compared to the same period last year.
- DEFINITY sales also saw a notable rise, increasing by 14.3% to $77.0 million, driven by market growth and opportunistic sales due to competitor supply challenges.

In conclusion, Lantheus Holdings experienced robust revenue growth in Q4 2024, driven primarily by the sales of its flagship products, PYLARIFY and DEFINITY. Despite this growth, there was a slight decline in net income compared to the previous year. The company's strategic investments and business development activities contributed to the increase in operating expenses.